Diabetes mellitus ve komplikasyonlarının tanı,tedavi ve izlem ...
Diabetes mellitus ve komplikasyonlarının tanı,tedavi ve izlem ...
Diabetes mellitus ve komplikasyonlarının tanı,tedavi ve izlem ...
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
6. Kronik böbrek hastal›¤› bulunmayan <strong>ve</strong> UAE normal olan diyabetli kiflilerde<br />
izole sistolik HT <strong>tedavi</strong>si için:<br />
ACE-‹ [S›n›f B, Düzey 2 kan›t (6)]<br />
ARB [S›n›f B, Düzey 2 kan›t (7)]<br />
Tiyazid grubu diüretik [S›n›f B, Düzey 2 kan›t (8,14)] <strong>ve</strong>ya<br />
Alternatif olarak uzun etkili DKKB [S›n›f C, Düzey 3 kan›t (15)] kullan›labilir.<br />
7. HT olan diyabetli kiflilerin HT <strong>tedavi</strong>sinde -blokerler birinci basamak <strong>tedavi</strong><br />
ajan› olarak önerilmemektedir [S›n›f A, Düzey 1A kan›t (16)].<br />
KAYNAKLAR<br />
1. Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular<br />
complications of type 2 diabetes (UKPDS 36): prospecti<strong>ve</strong> observational study. BMJ 2000;321:412-19.<br />
2. Orchard TJ, Forrest KY, Kuller LH, et al; Pittsburgh Epidemiology of <strong>Diabetes</strong> Complications Study. Lipid and blood pressure<br />
treatment goals for type 1 diabetes: 10-year incidence data from the Pittsburgh Epidemiology of <strong>Diabetes</strong> Complications<br />
Study. <strong>Diabetes</strong> Care 2001;24:1053-9.<br />
3. Schrier RW, Estacio RO, Esler A, et al. Effects of aggressi<strong>ve</strong> blood pressure control in normotensi<strong>ve</strong> type 2 diabetic patients<br />
on albuminuria, retinopathy and strokes. Kidney Int 2002;61:1086-97.<br />
4. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensi<strong>ve</strong> blood-pressure lowering and low-dose aspirin in patients<br />
with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.<br />
Lancet 1998;351:1755-62.<br />
5. UK Prospecti<strong>ve</strong> <strong>Diabetes</strong> Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications<br />
in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13.<br />
6. Heart Outcomes Pre<strong>ve</strong>ntion Evaluation Study In<strong>ve</strong>stigators. Effects of ramipril on cardiovascular and microvascular outcomes<br />
in people with diabetes <strong>mellitus</strong>: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-9.<br />
7. Lindholm LH, Ibsen H, Dahlof B, et al; LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes<br />
in the Losartan Inter<strong>ve</strong>ntion For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet<br />
2002;359:1004-10.<br />
8. Whelton PK, Barzilay J, Cushman WC, et al; ALLHAT Collaborati<strong>ve</strong> Research Group. Clinical outcomes in antihypertensi<strong>ve</strong><br />
treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensi<strong>ve</strong> and Lipid-<br />
Lowering Treatment to Pre<strong>ve</strong>nt Heart Attack Trial (ALLHAT). Arch Intern Med 2005;165:1401-9.<br />
9. Bakris GL, Gaxiola E, Messerli FH, et al; INVEST In<strong>ve</strong>stigators. Clinical outcomes in the diabetes cohort of the INternational<br />
VErapamil SR-Trandolapril study. Hypertension 2004;44:637-42.<br />
10. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin con<strong>ve</strong>rting-enzyme inhibition on diabetic nephropathy. The<br />
Collaborati<strong>ve</strong> Study Group. N Engl J Med 1993;329:1456-62.<br />
11. Lewis EJ, Hunsicker LG, Clarke WR, et al; Collaborati<strong>ve</strong> Study Group. Renoprotecti<strong>ve</strong> effect of the angiotensin-receptor<br />
antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.<br />
12. Brenner BM, Cooper ME, de Zeeuw D, et al; RENAAL Study In<strong>ve</strong>stigators. Effects of losartan on renal and cardiovascular<br />
outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.<br />
13. The ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all patients with type 1 diabetes <strong>mellitus</strong> and<br />
microalbuminuria recei<strong>ve</strong> angiotensin-con<strong>ve</strong>rting enzyme inhibitors? A meta-analysis of individual patient data. Ann Intern<br />
Med 2001;134:370-9.<br />
14. Curb JD, Pressel SL, Cutler JA, et al. Effect of diuretic-based antihypertensi<strong>ve</strong> treatment on cardiovascular disease risk<br />
in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperati<strong>ve</strong><br />
Research Group. JAMA 1996;276:1886-92.<br />
15. Tuomilehto J, Rastenyte D, Birkenhager WH, et al. Effects of calcium-channel blockade in older patients with diabetes and<br />
systolic hypertension. Systolic Hypertension in Europe Trial In<strong>ve</strong>stigators. N Engl J Med 1999;340:677-84.<br />
16. ALLHAT Collaborati<strong>ve</strong> Research Group. Major cardiovascular e<strong>ve</strong>nts in hypertensi<strong>ve</strong> patients randomized to doxazosin vs<br />
chlorthalidone: the antihypertensi<strong>ve</strong> and lipid-lowering treatment to pre<strong>ve</strong>nt heart attack trial (ALLHAT). JAMA 2000;283:1967-75.<br />
162 | DİABETES MELLİTUS VE KOMPLİKASYONLARININ TANI, TEDAVİ VE İZLEM KILAVUZU
Change language